- +1 858 909 0079
- +1 858 909 0057
- support@bioclone.net
- +1 858 909 0079
- support@bioclone.net
No products in the cart.
Cat# | Product Name | Swiss Prot# | Size | Price (US$) | Order |
PN1241 | Recombinant Protein-Newcastle disease virus Matrix protein (a.a.31 to 364) | Q9W7T8 | 100 µg | 1195 | |
PN1242 | Recombinant Protein-Newcastle disease virus Fusion glycoprotein F0 (a.a.35 to 125) | Q9Q9U0 | 100 µg | 1195 | |
PN1243 | Recombinant Protein-Newcastle disease virus Hemagglutinin-neuraminidase (a.a.43 to 571) | Q914X2 | 100 µg | 1195 | |
PN1244 | Recombinant Protein-Newcastle disease virus Nucleocapsid protein (a.a.22 to 489) | Q83853 | 100 µg | 1195 | |
PN1245 | Recombinant Protein-Newcastle disease virus Nucleoprotein (a.a.51 to 489) | B6VFP4 | 100 µg | 1195 | |
PN1246 | Recombinant Protein-Newcastle disease virus V protein (a.a.21 to 239) | B8YI12 | 100 µg | 1195 | |
PN1247 | Recombinant Protein-Newcastle disease virus Fusion glycoprotein F0 (a.a.32 to 178) | Q1W4A0 | 100 µg | 1195 | |
PN1248 | Recombinant Protein-Newcastle disease virus RdRp catalytic (a.a.634 to 818) | Q9DLD3 | 100 µg | 1195 | |
RPN1241 | cDNA-Newcastle disease virus Matrix protein (a.a.31 to 364) | Q9W7T8 | 2 µg | 1665 | |
RPN1242 | cDNA-Newcastle disease virus Fusion glycoprotein F0 (a.a.35 to 125) | Q9Q9U0 | 2 µg | 800 | |
RPN1243 | cDNA-Newcastle disease virus Hemagglutinin-neuraminidase (a.a.43 to 571) | Q914X2 | 2 µg | 2640 | |
RPN1244 | cDNA-Newcastle disease virus Nucleocapsid protein (a.a.22 to 489) | Q83853 | 2 µg | 2335 | |
RPN1245 | cDNA-Newcastle disease virus Nucleoprotein (a.a.51 to 489) | B6VFP4 | 2 µg | 2190 | |
RPN1246 | cDNA-Newcastle disease virus V protein (a.a.21 to 239) | B8YI12 | 2 µg | 1090 | |
RPN1247 | cDNA-Newcastle disease virus Fusion glycoprotein F0 (a.a.32 to 178) | Q1W4A0 | 2 µg | 730 | |
RPN1248 | cDNA-Newcastle disease virus RdRp catalytic (a.a.634 to 818) | Q9DLD3 | 2 µg | 920 |
Newcastle disease virus cDNA and recombinant antigen
Newcastle disease virus (NDV), also known as avian paramyxovirus 1, is a highly contagious virus that affects birds, particularly poultry. It can cause a range of symptoms, from mild respiratory signs to a severe and often fatal form of the disease known as velogenic Newcastle disease. The virus is widespread and can cause significant economic losses in the poultry industry. Vaccination is the main method of control, but early diagnosis and quarantine measures are also important in preventing the spread of the virus.
Newcastle disease virus (NDV) antigen refers to a substance or component of the NDV that is recognized by the immune system and triggers the production of antibodies. Antigens are commonly used in vaccines and diagnostic tests for NDV. In the case of NDV, the antigen may be a protein, glycoprotein, or other component of the virus that is recognized by the immune system. The production of NDV antigen can be done using recombinant DNA technology, where the viral gene encoding for the antigen is expressed in a host organism, such as bacteria or yeast. This can be used to produce large quantities of antigen for vaccine or diagnostic purposes.
The Newcastle disease virus (NDV) genome is the genetic material of the virus that contains all the information necessary for its replication and survival. The NDV genome is a single-stranded RNA molecule of negative polarity and is approximately 15 kilobases in length. The NDV genome encodes for six structural proteins (nucleocapsid, phosphoprotein, matrix protein, fusion protein, hemagglutinin-neuraminidase, and large polymerase) and two non-structural proteins (V protein and P protein). The genetic information contained in the NDV genome determines the virulence and pathogenesis of the virus, as well as its antigenicity. The knowledge of the NDV genome has contributed to the development of more effective vaccines and diagnostic tests for the virus.
Newcastle disease virus (NDV) is a highly contagious virus that affects birds, including domestic poultry and wild birds. It is a member of the Paramyxoviridae family and is characterized by its ability to cause severe respiratory and neurological disease in infected birds.
The matrix protein of NDV plays a key role in viral assembly and release by interacting with other viral proteins and the host cell membrane.
The fusion glycoprotein F0 is a precursor protein that is cleaved during viral replication to form the mature fusion protein. The fusion protein is responsible for the fusion of the viral envelope with the host cell membrane, which allows the virus to enter the host cell.
The hemagglutinin-neuraminidase (HN) protein is another glycoprotein that is found on the surface of the NDV virion. It is responsible for binding to host cell receptors and cleaving sialic acid residues, which promotes viral entry and prevents the aggregation of newly formed virions.
The nucleocapsid protein and nucleoprotein are structural proteins that are involved in viral RNA packaging and replication. They also play a role in inhibiting host cell gene expression and modulating the host immune response.
The V protein of NDV is a non-structural protein that plays a role in inhibiting the host interferon response, which allows the virus to evade the host immune system.
The RdRp catalytic subunit is an RNA-dependent RNA polymerase that is responsible for replicating the viral RNA genome. It is a target for antiviral drug development.
Research on NDV and its key components, including the matrix protein, fusion glycoprotein F0, hemagglutinin-neuraminidase, nucleocapsid protein, nucleoprotein, V protein, and RdRp catalytic subunit, is ongoing. While NDV is primarily a bird disease, there is concern that it could be transmitted to humans and cause severe respiratory illness. Understanding the mechanisms of NDV replication and immune evasion may aid in the development of effective antiviral therapies and vaccines.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.